Compare Cassava Sciences Inc (FLNA) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Funko Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Funko Inc trades at $6.58 (market cap $363.97M). The key difference: Funko Inc is far larger — about 9.2× Cassava Sciences Inc's market cap, and Funko Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Funko Inc for 33 Days on average.
| FLNA | FNKO | |
|---|---|---|
Market Cap | $39.40M | $363.97M |
Volume | 759,018 | 1,422,651 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $7.10 |
52-Week Low | $0.68 | $2.81 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | -$43.28M | $584.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Funko (FNKO) trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 EBITDA guidance to $105M. Revenue declined to $908M in 2025 but shows stabilization with 2026 projections at $933M. Analyst consensus is mixed with 42.9% buy ratings and $7.58 price target, representing 20% upside potential.
Investment opportunity centers on turnaround execution with improving margins and debt reduction. Key risks include negative net income margins, competitive pressures in collectibles, and sensitivity to consumer discretionary spending. The stock offers value with low P/S of 0.38x but requires sustained profitability improvement to justify higher valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
